analyst coverage

Why has CIR just paid out for two new analyst reports?
No new capital raising on the cards that I can see.
A deal on VGX-100 is not expected until 2013 at the earliest, post the Phase 1 clinical trials.
Are they just trying to prop up the share price to discourage any potential takeovers? Surely anyone serious about a TO would see the difference in price as small change?
All seems very mysterious to me - but then I am suspicious by nature.

Or am I just reading this wrong that Circadian commissioned the reports? If that is the case the increased interest can only be good news...